Loading clinical trials...
Loading clinical trials...
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2
Conditions
Interventions
GEN-003 Vaccine (30μg of each antigen)
GEN-003 Vaccine (60μg of each antigen)
+3 more
Locations
16
United States
University of Alabama Vaccine Research Unit
Birmingham, Alabama, United States
Medical Center for Clinical Research
San Diego, California, United States
Quest Clinical Research
San Francisco, California, United States
University of Illinois Department of Medicine
Chicago, Illinois, United States
Indiana University Infectious Disease Research
Indianapolis, Indiana, United States
The Fenway Institute
Boston, Massachusetts, United States
Start Date
January 1, 2015
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
October 16, 2017
Lead Sponsor
Genocea Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions